DB
ALLO icon

Dmitry Balyasny’s Allogene Therapeutics ALLO Stock Holding History

Dmitry Balyasny’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,182,816
Closed -$2.89M – 2973
2026
Q1 		$2.89M Buy
+1,182,816
New +$2.37M ﹤0.01% 1615
2024
Q3 		– Sell
-53,622
Closed -$125K – 2707
2024
Q2 		$125K Buy
53,622
+32,305
+152% +$95.3K ﹤0.01% 2390
2024
Q1 		$95.3K Buy
21,317
+5,587
+36% +$23.3K ﹤0.01% 2497
2023
Q4 		$50.5K Buy
+15,730
New +$44.6K ﹤0.01% 2407
2023
Q1 		– Sell
-168,388
Closed -$1.06M – 2601
2022
Q4 		$1.06M Buy
168,388
+126,909
+306% +$1.17M ﹤0.01% 1633
2022
Q3 		$448K Buy
+41,479
New +$564K ﹤0.01% 2067
2021
Q2 		– Sell
-98,208
Closed -$3.47M – 1932
2021
Q1 		$3.47M Buy
+98,208
New +$3.31M 0.02% 837
2020
Q4 		– Sell
-147,059
Closed -$5.55M – 1285
2020
Q3 		$5.55M Buy
+147,059
New +$5.54M 0.04% 575

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Dmitry Balyasny's ALLO Position: Q2 2026 in Review

Dmitry Balyasny sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 1,182,816 shares — an estimated $2.89M sold.

Dmitry Balyasny first reported a position in ALLO in Q3 2020 and held it in 8 quarters. The position peaked at $5.55M in Q3 2020. 207 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Dmitry Balyasny reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 1,182,816 Allogene Therapeutics shares in Q2 2026, an estimated $2.89M.
  • Dmitry Balyasny first reported a position in Allogene Therapeutics in Q3 2020 and held it in 8 quarters.
  • Dmitry Balyasny's Allogene Therapeutics position peaked at $5.55M in Q3 2020.
  • 207 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.